[Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. (CLPT) – Form 4 insider filing

CEO, President and Director Joseph M. Burnett reported the purchase of 1,424 common shares on 30 Jun 2025 through the company’s Employee Stock Purchase Plan (ESPP). The shares were acquired at $10.15, representing 85 % of the lower closing price on either the first or last day of the 1 Jan – 30 Jun 2025 purchase period, as permitted under the ESPP.

Following the transaction, Burnett’s direct ownership increased to 11,311 shares. He also continues to hold 243,522 shares indirectly via the Joseph M. Burnett Trust dated 20 Oct 2022.

No derivative securities were involved, and there were no dispositions reported. The filing is a routine disclosure under Section 16(a) and does not amend any prior filings. While the dollar value of the purchase (~US$14.5 k) is modest relative to Burnett’s existing indirect stake, insider buying can be viewed as a signal of management’s confidence in future prospects.

Positive

• CEO insider purchase adds 1,424 shares to direct holdings, signaling modest confidence.
• No insider selling reported in the filing, maintaining a positive governance tone.

Negative

• None.

Insights

Equity Analyst

TL;DR Small insider buy via ESPP; modestly positive sentiment, immaterial to float or valuation.

Burnett’s purchase increases his direct stake by roughly 14% to 11.3 k shares but remains less than 5 % of his total economic exposure when including the trust holdings. The acquisition price of $10.15 aligns with the ESPP’s 15% discount mechanism and is not indicative of open-market valuation. Given the scale (<US$15 k) and the automatic nature of ESPP participation, the transaction is unlikely to materially influence trading dynamics or the investment thesis. Nevertheless, the absence of insider selling and the continued accumulation by the CEO can be interpreted as a mild vote of confidence.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		A		1,424	A	$10.15(1)	11,311	D
Common Stock								243,522	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

2. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CLPT shares did the CEO purchase on 30 Jun 2025?

Joseph M. Burnett acquired 1,424 common shares under the ESPP.

At what price were the shares bought according to the Form 4?

The ESPP purchase price was $10.15 per share (85 % of the reference market price).

What is the CEO’s total direct shareholding after the transaction?

Burnett now directly owns 11,311 CLPT shares.

Does the CEO hold additional shares indirectly?

Yes. Through a trust, he indirectly holds 243,522 shares.

Were any derivative securities involved in this filing?

No derivative securities were reported in Table II.